bluebird bio
bluebird bio is a clinical-stage biotechnology company, focused on developing transformative gene therapies for severe genetic and rare diseases.
Founded in 2010, bluebird has the largest and deepest ex-vivo gene therapy data set in the world. The USA-based company has industry-leading programs for sickle cell disease, β-thalassemia and cerebral adrenoleukodystrophy and is advancing research to apply new technologies to these and other diseases.
Latest bluebird bio News & Features
10 May 2024
27 March 2024
Today's issue
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze